Vol. 5 No. 5 (2025)
Reimbursement Reviews

Pembrolizumab (Keytruda)

decorative image of the issue cover

Published May 15, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pembrolizumab (Keytruda), 100 mg per 4 mL vial, solution for infusion.
  • Indication: For the adjuvant treatment of adult patients with stage IB (T2a ≥ 4 cm), II, or IIIA non–small cell lung cancer (NSCLC) who have undergone complete resection and platinum-based chemotherapy.